These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8993356)

  • 1. Systemic and mucosal protective immunity to pneumococcal surface protein A.
    Briles DE; Tart RC; Wu HY; Ralph BA; Russell MW; McDaniel LS
    Ann N Y Acad Sci; 1996 Oct; 797():118-26. PubMed ID: 8993356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice.
    Nguyen CT; Kim SY; Kim MS; Lee SE; Rhee JH
    Vaccine; 2011 Aug; 29(34):5731-9. PubMed ID: 21696869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A.
    Langermann S; Palaszynski SR; Burlein JE; Koenig S; Hanson MS; Briles DE; Stover CK
    J Exp Med; 1994 Dec; 180(6):2277-86. PubMed ID: 7964500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice.
    Tart RC; McDaniel LS; Ralph BA; Briles DE
    J Infect Dis; 1996 Feb; 173(2):380-6. PubMed ID: 8568299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae.
    Briles DE; Ades E; Paton JC; Sampson JS; Carlone GM; Huebner RC; Virolainen A; Swiatlo E; Hollingshead SK
    Infect Immun; 2000 Feb; 68(2):796-800. PubMed ID: 10639448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type.
    McDaniel LS; Sheffield JS; Delucchi P; Briles DE
    Infect Immun; 1991 Jan; 59(1):222-8. PubMed ID: 1987036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae.
    Gor DO; Ding X; Briles DE; Jacobs MR; Greenspan NS
    Infect Immun; 2005 Mar; 73(3):1304-12. PubMed ID: 15731027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae.
    Wu HY; Nahm MH; Guo Y; Russell MW; Briles DE
    J Infect Dis; 1997 Apr; 175(4):839-46. PubMed ID: 9086139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection.
    Yamamoto M; McDaniel LS; Kawabata K; Briles DE; Jackson RJ; McGhee JR; Kiyono H
    Infect Immun; 1997 Feb; 65(2):640-4. PubMed ID: 9009325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection.
    Briles DE; Hollingshead S; Brooks-Walter A; Nabors GS; Ferguson L; Schilling M; Gravenstein S; Braun P; King J; Swift A
    Vaccine; 2000 Feb; 18(16):1707-11. PubMed ID: 10689153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae.
    Briles DE; Hollingshead SK; Nabors GS; Paton JC; Brooks-Walter A
    Vaccine; 2000 Dec; 19 Suppl 1():S87-95. PubMed ID: 11163470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies.
    da Silva MA; Converso TR; Gonçalves VM; Leite LCC; Tanizaki MM; Barazzone GC
    Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28637805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of pneumococcal surface protein A in the virulence of Streptococcus pneumoniae.
    Briles DE; Yother J; McDaniel LS
    Rev Infect Dis; 1988; 10 Suppl 2():S372-4. PubMed ID: 3187321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.
    Kothari N; Kothari S; Choi YJ; Dey A; Briles DE; Rhee DK; Carbis R
    Vaccine; 2015 Feb; 33(6):783-8. PubMed ID: 25545593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A protein chimera including PspA in fusion with PotD is protective against invasive pneumococcal infection and reduces nasopharyngeal colonization in mice.
    Converso TR; Goulart C; Darrieux M; Leite LCC
    Vaccine; 2017 Sep; 35(38):5140-5147. PubMed ID: 28818567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection elicited by nasal immunization with pneumococcal surface protein A (PspA) adjuvanted with bacterium-like particles against Streptococcus pneumoniae infection in mice.
    Li B; Chen X; Yu J; Zhang Y; Mo Z; Gu T; Kong W; Wu Y
    Microb Pathog; 2018 Oct; 123():115-119. PubMed ID: 29959043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic immunization with the region encoding the alpha-helical domain of PspA elicits protective immunity against Streptococcus pneumoniae.
    Bosarge JR; Watt JM; McDaniel DO; Swiatlo E; McDaniel LS
    Infect Immun; 2001 Sep; 69(9):5456-63. PubMed ID: 11500417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments.
    Lu J; Sun T; Wang D; Dong Y; Xu M; Hou H; Kong FT; Liang C; Gu T; Chen P; Sun S; Lv X; Jiang C; Kong W; Wu Y
    Immunol Invest; 2015; 44(5):482-96. PubMed ID: 26107747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice.
    Tada R; Suzuki H; Takahashi S; Negishi Y; Kiyono H; Kunisawa J; Aramaki Y
    Int Immunopharmacol; 2018 Aug; 61():385-393. PubMed ID: 29945026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a conjugate vaccine against invasive pneumococcal disease based on capsular polysaccharides coupled with PspA/family 1 protein of Streptococcus pneumoniae.
    Lin H; Peng Y; Lin Z; Zhang S; Guo Y
    Microb Pathog; 2015; 83-84():35-40. PubMed ID: 25959527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.